<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04307485</url>
  </required_header>
  <id_info>
    <org_study_id>2020HL</org_study_id>
    <nct_id>NCT04307485</nct_id>
  </id_info>
  <brief_title>A Study of Low Dose vs Standard Ticagrelor on Platelet Function After Intervention for Acute Coronary Syndrome in Senior Patients</brief_title>
  <official_title>A Randomized Controlled sTudy of Low Dose vs Standard tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Senior Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Tong Ren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Tong Ren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigates try to confirm our hypothesis that low dose ticagrelor(60mg)
      had similar anti-platelets function compared with the standard dose ticagrelor in senior ï¼ˆno
      less than 75 years old)acute coronary syndrome patients . Totally 60 senior ACS patients will
      be divided into 3 groups randomly one month after PCI . Group 1 will be treated with
      ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group; Group 2 will
      be treated with ticagrelor 90mg for 11 months after one month ticagreloar 90mg plus aspirin
      100 mg treatment after PCI; Group 3 will be treated with ticagrelor 60mg plus aspirin 100 mg
      for 11 months after one month standard DAPT treatment. The platelets function will be tested
      in VASP and TEG methods 2 months after PCI as the primary endpoints.The clinical events will
      be observed 12 months after PCI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes of PRI detected by VASP methods</measure>
    <time_frame>changes of PRI from baseline (4weeks after index PCI) to 8 and 12 weeks after index PCI</time_frame>
    <description>platelet reactivity index (PRI) detected by VASP (Vasodilator Stimulated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of Maximum Amplitude (MA) detected by TEG</measure>
    <time_frame>changes of MA from baseline (4weeks after index PCI) to 8 and 12 weeks after index PCI</time_frame>
    <description>Maximum Amplitude (MA) detected by TEG(Thromboelastography)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Senior Acute Coronary Syndrome Patients After PCI</condition>
  <arm_group>
    <arm_group_label>standard dose ticargrelor based DAPT therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treated with ticagrelor 90mg for 11 months after one month standard DAPT treatment after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose ticargrelor based DAPT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>90mg ticargrelor based DAPT vs 60mg ticargrelor based DAPT vs 90mg ticargrelor monotherapy</description>
    <arm_group_label>low dose ticargrelor based DAPT</arm_group_label>
    <arm_group_label>monotherapy</arm_group_label>
    <arm_group_label>standard dose ticargrelor based DAPT therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>aspirin</description>
    <arm_group_label>low dose ticargrelor based DAPT</arm_group_label>
    <arm_group_label>standard dose ticargrelor based DAPT therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Subject must be at least 75 years of age 2 Patients should have undergone successful
        percutaneous coronary intervention with drug-eluting stent for acute coronary syndrome
        3.Subject understand the study requirements and the treatment procedures and provided
        informed consent before the procedure

        Exclusion Criteria:

          1. Female of childbearing potential, unless a recent pregnancy test is negative, who
             possibly plan to become pregnant any time after enrollment into this study

          2. Active bleeding

          3. Known hypersensitivity or contraindication to study medications

          4. Female of childbearing potential, unless a recent pregnancy test is negative, who
             possibly plan to become pregnant any time after enrollment into this study

          5. Non-cardiac co-morbid conditions are present with life expectancy &lt;2 year or that may
             result in protocol non-compliance (per site investigator's medical judgment).

          6. Subjects with Cerebral hemorrhage history

          7. Subjects with stroke history in half a year

          8. subjects with active malignant tumor

          9. subjects with whom oral anticoagulants are needed

         10. Other conditions which the investigators think not applicable to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lei Hou, Doctor</last_name>
    <phone>13564868096</phone>
    <email>Dr_houlei@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>shanghai Tongren hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200336</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Hou, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 8, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>April 26, 2020</last_update_submitted>
  <last_update_submitted_qc>April 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Tong Ren Hospital</investigator_affiliation>
    <investigator_full_name>Hou Lei</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

